Dr. Lawler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
# F402
Aurora, CO 80045Phone+1 720-848-0000Fax+1 720-848-2653
Education & Training
- University of ColoradoFellowship, Endocrinology, Diabetes, and Metabolism, 2010 - 2013
- University of ColoradoResidency, Internal Medicine, 2007 - 2010
- Virginia Commonwealth University School of MedicineClass of 2007
Certifications & Licensure
- CO State Medical License 2010 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery Start of enrollment: 2019 May 10
Publications & Presentations
PubMed
- 28 citationsPREVENT: A Randomized, Placebo-Controlled Crossover Trial of Avexitide for Treatment of Post-Bariatric Hypoglycemia.Colleen M. Craig, Helen M. Lawler, Clare J. Lee, Marilyn Tan, Dawn Belt Davis
The Journal of Clinical Endocrinology and Metabolism. 2021-02-22 - 119 citationsAdipose Tissue Hypoxia, Inflammation, and Fibrosis in Obese Insulin-Sensitive and Obese Insulin-Resistant Subjects.Helen M. Lawler, Chantal Underkofler, Philip A. Kern, Christopher Erickson, Brooke C. Bredbeck
The Journal of Clinical Endocrinology and Metabolism. 2016-02-12 - 5 citationsTime to Dump Late Dumping Syndrome TerminologyElisa Rogowitz, Mary-Elizabeth Patti, Helen M. Lawler
Obesity Surgery. 2019-09-01
Press Mentions
- Xeris Pharmaceuticals Announces Positive Findings from the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric SurgeryMay 22nd, 2020
Professional Memberships
- Associate
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: